POST Online Media Lite Edition


Pfizer gets green light from FTC for Hospira acquisition

Staff writer |
Pfizer said the U.S. Federal Trade Commission (FTC) terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Hospira.

Article continues below

The FTC’s clearance is contingent upon Pfizer’s commitment to divest four U.S. sterile injectable assets, including Acetylcysteine, Clindamycin, Voriconazole and Melphalan.

In addition, Pfizer announced that Brazil’s Superintendency-General of CADE has published its unconditional clearance decision.

“We are pleased to have received these final regulatory approvals for our pending acquisition of Hospira,” said Ian Read, Chairman and Chief Executive Officer, Pfizer.

“We now look forward to combining our two companies and expect the transaction to close in early September.”

What to read next

Pfizer offers concessions to win approval for $15bn Hospira takeover
Pfizer has green light from EU for $15 billion Hospira acquisition
Pfizer completes Hospira acquisition